BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection by preventing HA-mediated viral entry. The nanoparticles comprise icosahedral bacteriophage capsid proteins conjugated to mono-ethylene glycol-linked sialic acid, which...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver vaccines....
BioCentury | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

Deerfield forms Orchard Innovations in Yeda collaboration on translation Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on Friday after the company said FDA advised it to conduct a second Phase III study of PXT3003 prior...
BioCentury | Aug 26, 2019
Product Development

Vax to the future: How Anthony Fauci is thinking about next-gen vaccines and other NIAID priorities

From his vantage point overseeing NIH’s infectious disease agenda, Anthony Fauci has identified vaccine development as an area poised to make big leaps. He says the institute’s prioritization of platform technologies holds more promise than...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

...A virus matrix protein M1 (M1) Influenza A virus matrix protein M2 (M2) Influenza A virus nucleoprotein (NP) Influenza B virus hemagglutinin (Influenza B HA) Influenza...
BioCentury | Apr 5, 2019
Clinical News

NIH begins universal flu vaccine trial

NIH has begun dosing subjects in a Phase I trial of its universal flu vaccine, with data readouts expected in early 2020. The open-label, U.S. trial assessing safety and production of anti-influenza virus antibodies is...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Small molecule HA inhibitor for treating H1, H5 flu infections

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Cell culture and mouse studies identified a small molecule HA inhibitor that could help treat H1 and H5 influenza A infections. In vitro screening of a compound library...
BioCentury | Mar 8, 2019
Preclinical News

Janssen, Scripps discover small molecule for flu

Janssen and Scripps have generated an oral compound for treating flu that inhibits the HA protein on influenza H1 and H5 strains. Recent studies have led to the development of broadly neutralizing antibodies (bNAbs) that...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest an inactivated influenza virus vaccine expressing monoglycosylated HA could help prevent infection by multiple influenza A virus strains. The vaccine consists of inactivated H1N1 influenza virus particles modified to...
Items per page:
1 - 10 of 96